Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is a phase 3 interventional study registered as NCT04498117, led by CanariaBio with Gynecologic Oncology and IQVIA Pty, and active but no longer recruiting on the registry. Official title: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. Planned enrolment is 615 participants (actual). The study started in 2020-08-25 and primary completion is expected in 2026-12-26. No results have been posted on ClinicalTrials.gov.